Sino Biopharmaceutical (1177.HK) Earnings Analysis
Sino Biopharmaceutical (1177.HK) next reports earnings on 2026-08-26, consensus EPS 0.1386 HKD. Last quarter (2026-03-26) it missed with EPS 0.01113 HKD vs 0.06718 HKD est (-83.4%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 34.43.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1177.HK next report earnings?
| Next earnings date | 2026-08-26 |
|---|---|
| Consensus EPS estimate | 0.1386 HKD |
| Revenue estimate | 23.21B |
1177.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-26 | 0.01113 HKD | 0.06718 HKD | -83.4% | Miss |
| 2025-08-18 | 0.2048 HKD | 0.1307 HKD | +56.7% | Beat |
| 2025-03-20 | 0.0851 HKD | 0.08515 HKD | -0.1% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
1177.HK valuation and analyst view
| Trailing P/E | 34.43 |
|---|---|
| Trailing EPS | 0.13017 HKD |
| Price / book | 2.63 |
| Dividend yield | 1.93% |
| Market cap | 95.31B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Sino Biopharmaceutical (1177.HK)'s next earnings date?
Sino Biopharmaceutical is next scheduled to report on 2026-08-26, with a consensus EPS estimate of 0.1386 HKD and revenue estimate of 23.21B.
Did 1177.HK beat earnings last quarter?
In its 2026-03-26 report, 1177.HK posted EPS of 0.01113 HKD versus a 0.06718 HKD estimate — a miss of 83.4%.
What is 1177.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 1177.HK beat estimates 1 times (33%).
What is 1177.HK's current P/E ratio and EPS?
1177.HK trades at a trailing P/E of 34.43 on trailing EPS of 0.13017472178032508 HKD.
What do analysts rate 1177.HK?
1177.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.